{"id":443687,"date":"2026-05-25T01:19:07","date_gmt":"2026-05-25T01:19:07","guid":{"rendered":"https:\/\/www.newsbeep.com\/nz\/443687\/"},"modified":"2026-05-25T01:19:07","modified_gmt":"2026-05-25T01:19:07","slug":"what-is-morgans-updated-view-on-this-red-hot-asx-healthcare-stock","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/nz\/443687\/","title":{"rendered":"What is Morgan’s updated view on this red hot ASX healthcare stock?"},"content":{"rendered":"

It has been a red hot 2026 for ASX healthcare stock Vitrafy Life Sciences Ltd (ASX:VFY<\/a>).\u00a0<\/p>\n

Vitrafy researches and develops cryopreservation technology. The company offers cryopreservation devices, thawing devices, packaging, and software platform.<\/p>\n

In 2026, it has risen an impressive 107%.\u00a0<\/p>\n

This included a 13% jump last Friday after the company released an announcement<\/a> to the ASX.\u00a0<\/p>\n

\"a<\/p>\n

Image source: Getty Images<\/p>\n

What did the company announce?<\/p>\n

On Friday, the healthcare company announced<\/a> the successful completion of the Phase II in-vitro study with United States Army Institute of Surgical Research (part of the Defense Health Agency) (“USAISR”).\u00a0<\/p>\n

According to the release, excellent results were achieved using the Vitrafy cryopreservation ecosystem across all tested protocols when compared to existing regulatory and quality guidelines for platelet use.<\/p>\n

Building upon the Phase I results, the Phase II USAISR in-vitro results highlight that all protocols tested via Vitrafy’s cryopreservation ecosystem outperform the existing regulatory and quality guidelines currently set for the use of platelets<\/p>\n

What does this all mean?<\/p>\n

The company tested different ways of freezing and thawing platelets (blood components used to stop bleeding).<\/p>\n

All methods passed the minimum medical standards needed for human use.<\/p>\n

One method in particular \u2013 using 3% DMSO without needing a “wash” step \u2013 performed best.<\/p>\n

Normally frozen platelets are difficult and expensive to prepare after thawing.<\/p>\n

Vitrafy’s “no-wash” process means hospitals, ambulances, military units, or remote clinics could potentially thaw and use platelets quickly without special lab equipment or trained technicians.<\/p>\n

That could make it easier to store emergency blood supplies for disasters, trauma care, rural medicine, and battlefield injuries.<\/p>\n

They achieved 94% platelet recovery after thawing, which means most platelets survived the freezing process and still functioned properly.<\/p>\n

They also maintained strong clotting ability, which is critical in trauma situations.<\/p>\n

Investors were seemingly pleased with these results, as the ASX healthcare stock rose 13% last Friday following the release.\u00a0<\/p>\n

What is Morgan’s take?<\/p>\n

Following this announcement, the team at Morgans provided updated guidance on this ASX healthcare stock.\u00a0<\/p>\n

It said Vitrafy has released final Phase II in-vitro platelet results from USAISR, with all three cryopreservation protocols exceeding fresh-platelet quality benchmarks.\u00a0<\/p>\n

The headline result was 94% post-thaw recovery using the 3% DMSO no-wash protocol, well ahead of the FDA\/AABB (~75%) and European (~50%) thresholds. The study is independently authored by the US Army across 20 donors and 60+ samples at commercial volumes, delivering on a core IPO commitment made at listing in November 2024.\u00a0<\/p>\n

No FDA-approved no-wash frozen platelet product exists commercially in the US, positioning Vitrafy to address a genuine category gap. Shares trading up strongly from the $1.20 YTD lows, and +27% on the 2024 IPO price.<\/p>\n

This ASX healthcare stock closed trading last week at $2.65.\u00a0<\/p>\n

Current targets from brokers<\/a> are hovering around the $3.00 mark.\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"It has been a red hot 2026 for ASX healthcare stock Vitrafy Life Sciences Ltd (ASX:VFY).\u00a0 Vitrafy researches…\n","protected":false},"author":2,"featured_media":443688,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[134,527,111,139,69],"class_list":["post-443687","post","type-post","status-publish","format-standard","has-post-thumbnail","category-healthcare","tag-health","tag-healthcare","tag-new-zealand","tag-newzealand","tag-nz"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts\/443687","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/comments?post=443687"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts\/443687\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/media\/443688"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/media?parent=443687"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/categories?post=443687"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/tags?post=443687"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}